ORIC
ORIC Pharmaceuticals, Inc.NASDAQHealthcare$8.89+18.93%ClosedMarket Cap: $892.2M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.04
P/S
0.00
EV/EBITDA
-6.44
DCF Value
$0.35
FCF Yield
-12.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-38.8%
ROA
-31.5%
ROIC
-36.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-34.6M | $-30.5M | $-0.30 | — |
| FY 2025 | $0.00 | -Infinity% | $-143.0M | $-129.5M | $-1.47 | — |
| Q3 2025 | $0.00 | NaN% | $-36.7M | $-32.6M | $-0.33 | — |
| Q2 2025 | $0.00 | NaN% | $-39.1M | $-36.4M | $-0.47 | — |
| Q1 2025 | $0.00 | NaN% | $-32.7M | $-30.0M | $-0.42 | — |
| Q4 2024 | $0.00 | -Infinity% | $-39.6M | $-36.3M | $-0.51 | — |
| FY 2024 | $0.00 | -Infinity% | $-142.9M | $-127.8M | $-1.83 | — |
| Q3 2024 | $0.00 | NaN% | $-38.3M | $-34.6M | $-0.49 | — |
| Q2 2024 | $0.00 | NaN% | $-36.0M | $-32.0M | $-0.45 | — |
| Q1 2024 | $0.00 | -Infinity% | $-29.0M | $-25.0M | $-0.37 | — |
| Q4 2023 | $0.00 | -Infinity% | $-31.4M | $-28.3M | $-0.49 | — |
| FY 2023 | $0.00 | -Infinity% | $-110.8M | $-100.7M | $-1.96 | — |